|Bid||259.00 x 800|
|Ask||269.00 x 1400|
|Day's Range||255.76 - 261.37|
|52 Week Range||202.83 - 282.98|
|Beta (3Y Monthly)||1.30|
|PE Ratio (TTM)||35.88|
|Earnings Date||Apr 24, 2019|
|Forward Dividend & Yield||0.76 (0.28%)|
|1y Target Est||285.27|
Strong analytical instruments business, product portfolio expansion and prudent growth strategy are likely to support Thermo Fisher (TMO) in Q1. However, forex might act as a dampener.
We are optimistic about Boston Scientific's (BSX) IC business that will help maintain its impressive global growth trend in Q1 owing to an innovative portfolio and strong commercial teams.
Thermo Fisher (TMO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Despite ongoing customers' transition from HiSeq consumables to NovaSeq, Illumina's (ILMN) Q1 results are expected to gain from this high throughput suite.
Abbott (ABT) expects high single-digit growth in Medical Devices' sales in first-quarter 2019 and continued double-digit growth in certain sub-segments.
Since Thermo Fisher Scientific Inc. (NYSE:TMO) released its earnings in December 2018, analysts seem cautiously optimistic, with profits predicted to increase by 18% next year...
The Zacks Analyst Blog Highlights: Mastercard, Honeywell, Thermo Fisher, Cigna and Norfolk Southern
Zacks.com featured expert Kevin Matras highlights: SS &C Technologies, Thermo Fisher Scientific, Columbia Sportswear, Heidrick & Struggles International and Anthem
Thermo Fisher (TMO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
While his company reached new heights over the last year, pay for the chief executive of one of Massachusetts’ largest and most valuable life sciences companies experienced declined by 17 percent.
Thermo Fisher (TMO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
WALTHAM, Mass. , April 1, 2019 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the first quarter ...
Biogen's pipeline pitfall casts doubt on its strategy. Meanwhile, a shareholder revolt threatens Bristol-Myers' tie-up with Celgene.
NEW YORK, March 27, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]
On closure of the acquisition deal, Brammer Bio will be integral to Thermo Fisher's (TMO) pharma services business within its Laboratory Products and Services wing.
Jim Cramer chats with Thermo Fisher Scientific CEO Marc Casper about the rise of individualized medicine and where he sees the biotech industry is headed.